Orthopedic Titan Bets on Biotech to Solve a Crisis Devices Can't Fix

PITTSBURGH, PA – August 18, 2026

In the world of medical technology, career trajectories are often predictable. Executives build expertise within a specific domain—be it surgical robotics, imaging, or diagnostics—and ascend the ranks of established industry giants. It is rare to see a leader at the pinnacle of the hardware-centric orthopedic device world make a deliberate leap into the volatile, high-stakes arena of clinical-stage biotechnology. Yet, that is precisely the signal sent by Tim Czartoski’s recent appointment to the board of Peptilogics.

Czartoski is not a peripheral player. As the former president of DePuy Synthes's $5.4 billion U.S. orthopedics business and, more recently, a senior leader at Enovis, he has spent his career commercializing the very steel, polymer, and robotic systems that define modern orthopedics. His move to join the board of a company whose primary asset is a novel anti-infection drug, zaloganan, is more than a personnel announcement; it’s a critical assessment of the industry’s limitations from one of its most seasoned insiders. As Czartoski himself stated, “Infection is the most significant, unsolved problem in orthopedics... Devices alone aren't going to solve this.” This admission from a titan of the device industry is a powerful validation of a long-simmering truth: for some of medicine’s most intractable problems, the solution may not come from a better screw or a smarter robot, but from a vial.

The Billion-Dollar Plague in Our Joints

To understand the significance of this move, one must first grasp the catastrophic scale of prosthetic joint infection (PJI). Each year, surgeons in the U.S. perform over a million hip and knee replacements, marvels of engineering that restore mobility to an aging population. But for up to 45,000 of those patients annually, the procedure becomes a gateway to a devastating, life-altering complication. PJI is not a simple infection; it is a siege. Bacteria, introduced during surgery or seeded from elsewhere in the body, colonize the implant surface and form a slimy, impenetrable fortress known as a biofilm.

This biofilm renders systemic antibiotics largely ineffective, leaving surgeons with a brutal set of options. The standard of care, known as debridement, antibiotics, and implant retention (DAIR), involves surgically opening the joint, scraping away infected tissue, and bathing the implant, followed by a long course of antibiotics. Even so, failure rates hover between 15% and 50%. When DAIR fails, patients face multiple, debilitating surgeries, often culminating in the complete removal of the artificial joint, months of IV antibiotics, and a high-risk revision surgery. The toll is immense: the 5-year mortality rate for PJI is higher than that of breast or prostate cancer, and the annual hospital costs are projected to eclipse $1.8 billion by 2030 in the U.S. alone. For over fifty years, the industry’s response has been iterative improvements to surgical technique and implant materials, but the core problem of biofilm has remained stubbornly unsolved.

A New Weapon for an Old War

Enter Peptilogics, a Pittsburgh-based biotech firm armed with a computational drug design platform and a lead candidate, zaloganan, aimed directly at the heart of the PJI crisis. Zaloganan is not another antibiotic; it is a first-in-class, broad-spectrum anti-biofilm drug. Its engineered peptide structure is designed to physically disrupt bacterial membranes, killing pathogens on contact and, critically, penetrating the protective biofilm to eradicate the bacteria hiding within. This represents a fundamental shift in strategy—from trying to starve the fortress to blowing a hole in its walls.

Early results have been compelling. A Phase 1b trial showed that 13 of 14 patients with PJI who received a single zaloganan irrigation during their DAIR procedure remained infection-free after one year—a striking improvement over the historical failure rates. Bolstered by this data and a war chest of over $120 million from investors including Peter Thiel’s Founders Fund and the AMR Action Fund, Peptilogics is now enrolling patients in a pivotal Phase 2/3 registration trial. The FDA has already granted the drug a trifecta of designations—Qualified Infectious Disease Product (QIDP), Orphan Drug, and Fast Track—signaling a clear regulatory path for a therapy addressing a critical unmet need. Peptilogics CEO Jonathan Steckbeck, Ph.D., put it plainly: “The only real tool surgeons have had against device-related infections is more surgery. We are aiming to change that with zaloganan.”

The Commercialization Challenge: From Lab to Launch

Developing a promising drug is only half the battle. The history of biotechnology is littered with innovative therapies that failed not in the clinic, but in the marketplace. This is where Czartoski’s appointment transforms from an interesting development into a masterstroke of strategic planning. Launching zaloganan is not a typical pharmaceutical sales challenge; it requires changing the fundamental workflow and mindset of orthopedic surgeons, a group notoriously resistant to practice changes without overwhelming evidence and a seamless integration plan.

This is a challenge Czartoski knows intimately. His experience launching complex robotic platforms at the world’s largest orthopedic companies involved exactly this kind of paradigm shift. He understands the institutional hurdles, the surgeon--hospital dynamics, and the intricate sales channels required to introduce a new technology into the operating room. As Steckbeck noted, “He's led billion-dollar launches at the largest orthopedic companies in the world, and he knows what it takes to change surgical practice.” Czartoski brings not just a network, but a playbook for commercial execution in one of medicine’s most conservative fields. His presence on the board provides the commercial credibility to match the company’s scientific innovation, reassuring investors and future partners that Peptilogics is building not just a molecule, but a market-ready solution. The fusion of Czartoski’s deep-rooted orthopedic commercial expertise with Peptilogics’ cutting-edge therapeutic approach creates a formidable combination, poised to finally offer a meaningful answer to a problem that has plagued patients and surgeons for decades.